EDN1 and cancer: ET1 has a plasma half-life of only 1 min, therefore, its pathophysiological effects depend on its continuous production by ECE1 and degradation by NEP, positioning these two proteins as potential targets to modulate the impact of ET1 in this cancer [5, 6].